Amgen’s cancer drug fails to increase overall survival rate
THOUSAND OAKS, Calif. Despite prolonging survival without disease progression in patients with metastatic colorectal cancer, an investigational drug from Amgen failed to increase overall survival in a late-stage clinical trial, the biotech company said Thursday.
Amgen announced results of a phase 3 clinical trial of Vectibix (panitumumab) administered with the chemotherapy drug FOLFOX as a first-line treatment for the cancer.
An analysis of the study showed that the combination of Vectibix and FOLFOX increased overall survival of two years, compared with slightly less than 20 months in patients treated with FOLFOX alone, though the results were not statistically significant.
Teva rolls out antihistamine generic
NORTH WALES, Pa. Generic drug maker Teva Pharmaceuticals has introduced a generic version of a prescription antihistamine.
The Israel-based drug maker’s U.S. subsidiary announced the introduction of fexofenadine hydrochloride and pseudoephedrine hyrdochloride extended-release tablets in the 60-mg/120-mg strength.
The drug is a generic version of Sanofi-Aventis’ Allegra-D and is designed to provide 12-hour relief from allergy symptoms. Allegra products had global sales of $1.02 billion in 2008, according to Sanofi-Aventis financial data.
NACDS, RollStream develop CPSIA Certificate Exchange Network
ALEXANDRIA, Va. The National Association of Chain Drug Stores, with its technology partner RollStream, earlier this month joined together to develop a new tool — the CPSIA Certificate Exchange Network — to assist NACDS members in complying with an upcoming requirement from the Consumer Product Safety Improvement Act of 2008.
Signed into law in August 2008 and effective by February 2010, CPSIA requires manufacturers to provide general conformance certificates (certificates that certify the product in question is in compliance with all relative regulations) to retailers and distributors with each shipment. The law currently affects all products in commerce that are regulated by the Consumer Product Safety Commission.
“It’s everything from prescription products, over-the-counter medicines, cosmetics [and] toys,” said Steve Perlowski, NACDS VP member relations and industry affairs, during a presentation Nov. 4.
The network enables suppliers to post general conformance certificates on a central network powered by RollStream that can be readily accessed by retailers.
To help educate retailers and manufacturers about the new requirement and the Certificate Exchange Network, NACDS is hosting a series of educational webinars each Wednesday in November, from 3 p.m. to 4 p.m. Click here to register for one of the upcoming webinars.